119 related articles for article (PubMed ID: 25738879)
1. Recombinant receptor activator of nuclear factor κB exhibits more marked inhibitory effects on osteoclasts compared with recombinant osteoprotegerin in vitro and in vivo.
Xiong Q; Xin L; Zhang L; Tang P; Zhang L
Mol Med Rep; 2015 Jul; 12(1):631-8. PubMed ID: 25738879
[TBL] [Abstract][Full Text] [Related]
2. [Effects of recombinant human osteoprotegerin and recombinant RANK protein on the differentiation of osteoclast precursors].
Xiong Q; Zhang LC; Zhang LH; Yao Q; Tang P
Zhongguo Gu Shang; 2013 Apr; 26(4):324-7. PubMed ID: 23844495
[TBL] [Abstract][Full Text] [Related]
3. [Effect of recombinant human osteoprotegerin on osteoclasts stimulated by polyethylene particles].
Zhang H; Huang C; Chen S
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Aug; 22(8):979-83. PubMed ID: 18773818
[TBL] [Abstract][Full Text] [Related]
4. [In vitro study of combination rhOPG-Fc and alendronate on inhibition osteoclast].
Huang P; Wang Y; Chi ZY; Yang ZY; Ni J; Yang WJ; Wang RD; Bai JZ
Zhonghua Wai Ke Za Zhi; 2005 Jun; 43(12):812-6. PubMed ID: 16083587
[TBL] [Abstract][Full Text] [Related]
5. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
6. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
Regmi A; Fuson T; Yang X; Kays J; Moxham C; Zartler E; Chandrashekhar S; Galvin RJ
Bone; 2005 Feb; 36(2):284-91. PubMed ID: 15780954
[TBL] [Abstract][Full Text] [Related]
7. Up-regulated CST5 inhibits bone resorption and activation of osteoclasts in rat models of osteoporosis via suppression of the NF-κB pathway.
Wang F; Zhang C; Ge W; Zhang G
J Cell Mol Med; 2019 Oct; 23(10):6744-6754. PubMed ID: 31402549
[TBL] [Abstract][Full Text] [Related]
8. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.
Capparelli C; Morony S; Warmington K; Adamu S; Lacey D; Dunstan CR; Stouch B; Martin S; Kostenuik PJ
J Bone Miner Res; 2003 May; 18(5):852-8. PubMed ID: 12733724
[TBL] [Abstract][Full Text] [Related]
9. Murine RANK protein's inhibition of bone resorption.
Zhang J; Zhang L; Xu M; Zhang L; Tang P; Jiang C
J Craniofac Surg; 2011 Nov; 22(6):2084-9. PubMed ID: 22067870
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitory effect of recombinant receptor activator of nuclear factor kappaB protein on bone loss in ovariectomized mice].
Zhang LC; Lü HC; Xiong Q; Zhang LH; Tang PF
Zhongguo Gu Shang; 2013 May; 26(5):414-8. PubMed ID: 23937037
[TBL] [Abstract][Full Text] [Related]
11. Low‑molecular weight fucoidan inhibits the differentiation of osteoclasts and reduces osteoporosis in ovariectomized rats.
Jin X; Zhu L; Li X; Jia J; Zhang Y; Sun X; Ma J; Liu Z; Ma X
Mol Med Rep; 2017 Feb; 15(2):890-898. PubMed ID: 28000877
[TBL] [Abstract][Full Text] [Related]
12. Suppression Effect of Astaxanthin on Osteoclast Formation In Vitro and Bone Loss In Vivo.
Hwang YH; Kim KJ; Kim SJ; Mun SK; Hong SG; Son YJ; Yee ST
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562730
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.
Kostenuik PJ; Bolon B; Morony S; Daris M; Geng Z; Carter C; Sheng J
Bone; 2004 Apr; 34(4):656-64. PubMed ID: 15050896
[TBL] [Abstract][Full Text] [Related]
14. Retrovirus-mediated gene transfer of receptor activator of nuclear factor-kappaB-Fc prevents bone loss in ovariectomized mice.
Kim D; Cho SW; Her SJ; Yang JY; Kim SW; Kim SY; Shin CS
Stem Cells; 2006 Jul; 24(7):1798-805. PubMed ID: 16556708
[TBL] [Abstract][Full Text] [Related]
15. Puerarin prevents bone loss in ovariectomized mice and inhibits osteoclast formation in vitro.
Yuan SY; Sheng T; Liu LQ; Zhang YL; Liu XM; Ma T; Zheng H; Yan Y; Ishimi Y; Wang XX
Chin J Nat Med; 2016 Apr; 14(4):265-269. PubMed ID: 27114313
[TBL] [Abstract][Full Text] [Related]
16. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
17. Effect of osteoprotegerin in combination with interleukin-6 on inhibition of osteoclast differentiation.
Wang X; Luo Y; Liao WB; Zhang J; Chen TM
Chin J Traumatol; 2013; 16(5):277-80. PubMed ID: 24103822
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotective effects of osthole in a mouse model of 5/6 nephrectomy through inhibiting osteoclast formation.
Li X; Xue C; Wang L; Tang D; Huang J; Zhao Y; Chen Y; Zhao D; Shi Q; Wang Y; Shu B
Mol Med Rep; 2016 Oct; 14(4):3769-76. PubMed ID: 27571745
[TBL] [Abstract][Full Text] [Related]
19. The prenyl group contributes to activities of phytoestrogen 8-prenynaringenin in enhancing bone formation and inhibiting bone resorption in vitro.
Ming LG; Lv X; Ma XN; Ge BF; Zhen P; Song P; Zhou J; Ma HP; Xian CJ; Chen KM
Endocrinology; 2013 Mar; 154(3):1202-14. PubMed ID: 23389955
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and disposition of recombinant human osteoprotegerin (rhOPG) after intravenous administration in female fischer rats.
Miyaji Y; Kurihara A; Kamiyama E; Shiiki T; Kawai K; Okazaki O
Xenobiotica; 2009 Feb; 39(2):113-24. PubMed ID: 19255937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
